Browse

The Lack of CD34 Expression in Gastrointestinal Stromal Tumors is Related to Cystic Degeneration Following Imatinib Use

Cited 4 time in Web of Science Cited 4 time in Scopus
Authors
Koh, Youngil; Lee, Hee Eun; Oh, Do-Youn; Kim, Jee Hyun; Lee, Se-Hoon; Kim, Se Hyung; Kim, Dong-Wan; Im, Seock-Ah; Kim, Tae-You; Heo, Dae Seog; Kim, Woo-Ho; Bang, Yung-Jue
Issue Date
2012-11
Citation
Japanese Journal of Clinical Oncology, Vol.42 No.11, pp.1020-1027
Keywords
gastrointestinal stromal tumorimatinibVEGFCD34Chois criteria
Abstract
We evaluated the characteristics of the gastrointestinal stromal tumors that showed discrepancies between their assessment using the Response Evaluation Criteria in Solid Tumor (RECIST) and Chois criteria. We also investigated the clinical applicability of Chois criteria to Korean gastrointestinal stromal tumor patients undergoing imatinib therapy. Patients with advanced gastrointestinal stromal tumors treated with frontline imatinib were analyzed. Computed tomography images of these patients were reviewed and genotyping for the KIT and PDGFRA genes was performed. Immunohistochemical staining of c-KIT, CD34, platelet derived growth factor receptor-alpha, platelet derived growth factor receptor-beta, AKT, P-ERK and vascular endothelial growth factor was followed. Ninety-five patients were enrolled. When using Chois criteria to evaluate the 61 patients who achieved at least partial response by Chois criteria, 27 patients showed discrepancies in their response to treatment between these two sets of criteria. A lack of CD34 expression in tumors was found to be related to cystic degeneration after imatinib treatment (P 0.001). Patients who showed partial response by Chois criteria but stable disease by RECIST criteria had a similar progression-free survival to cases who showed a partial response under both systems (P 0.951). Gastrointestinal stromal tumors showing cystic degeneration after imatinib treatment lack CD34 expression. Chois criteria have a clinical value in terms of the progression-free survival in Korean patients treated with imatinib.
ISSN
0368-2811
URI
https://hdl.handle.net/10371/165502
DOI
https://doi.org/10.1093/jjco/hys138
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse